| [1] |
Kong X, Moran MS, Zhang N, et al. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients[J].Eur J Cancer,2011, 47(14):2084-90.
|
| [2] |
Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome [J]. J Clin Oncol，2007，25(19):2650-5.
|
| [3] |
Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual[M].7th ed.New York: Springer, 2010:347-76.
|
| [4] |
Hammond ME, Hayes DF, Dowsett M,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Clin Oncol,2010,28(16):2784-95.
|
| [5] |
Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment[J].BMC Cancer,2011,11:486.
|
| [6] |
Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].Arch Pathol Lab Med,2007,131(1):18-43.
|
| [7] |
Shao ZM.Chinese anti-cancer association guideline for breast cancer (2011 edition) [J].Zhongguo Ai Zheng Za Zhi,2011,21（5）:367-417.[邵志敏.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂 志,2011,21（5）:367-417.]
|
| [8] |
Hugh J, Hanson J, Cheang MC,et al. Breast cancer subtypes and response to docetaxel in node- positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial[J]. J Clin Oncol, 2009,27(8): 1168-76.
|
| [9] |
Park S, Koo JS, Kim MS，et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry[J]. Breast,2012,21(1)：50-7.
|
| [10] |
Liu QM，Cao YL，Wu XB，et al.Clinical value of molecular subtypes for breast cancer prognosis of dose dense docetaxel meoadjuvant chemotherapy[J]. Zhong Liu Fang Zhi Yan Jiu，2013，40(1)：59-54.[ 刘秋明，曹亚丽，吴晓波，等.乳腺癌分子分型在多西他赛密集新辅助化疗疗效及预后中的预测价值[J].肿瘤防治 研究，2013，40（1）：59-64.]
|
| [11] |
Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors[J]. J Clin Oncol, 2006,24(7):1037-44.
|
| [12] |
Li X, Liu M, Zhang YJ, et al. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer[J]. Med Oncol, 2011，28 Suppl 1：S31-8.
|
| [13] |
Learn PA, Yeh IT, McNutt M, et al. Her 2/neu expression as a predictor of response neoadjuvant docetaxel in atients with operable breast carcinoma[J]. Cancer,2005,103(11):2252-60.
|
| [14] |
Toi M, Nakamura S, Kuroi K,et al. Phase Ⅱ study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival[J]. Breast Cancer Res Treat, 2008,110 (3):531-9.
|
| [15] |
Noske A, Loibl S, Darb-Esfahani S, et al. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: Prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)[J].Breast Cancer Res Treat,2011,126(1):109-17.
|
| [16] |
Jones RL, Salter J, A'Hern R, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer [J]. Breast Cancer Res Treat, 2010,119(2):315-23.
|
| [17] |
Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy [J].Eur J Cancer , 2004,40(2):205-11.
|
| [18] |
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: Dealing with the diversity of breast cancer-Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer [J]. Ann Oncol, 2011, 22(8):1736-47.
|
| [19] |
Perou CM, S rlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature，2000 ，406(6797):747-52.
|
| [20] |
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J].J Clin Oncol,2008,26(8):1275-81.
|
| [21] |
Wu J, Li S, Jia W, et al. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer[J].J Cancer Res Clin Oncol,2011,137 (10):1505-10.
|
| [22] |
Darb-Esfahani S, Loibl S, Muller BM, et al. Identication of biology based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy[J].Breast Cancer Res, 2009,11(5):R69.
|
下载:
